Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Demystifying DAF Sludge

Have you ever twisted the top on a new bottle of soda to see bubbles appear, seemingly out of nowhere, and rise to the top? Do you remember the sound you heard when you twisted the cap? Odds are you know exactly what I’m talking about. But have you ever wondered exactly what’s going on…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Demystifying DAF Sludge

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Have you ever twisted the top on a new bottle of soda to see bubbles appear, seemingly out of nowhere, and rise to the top? Do you remember the sound you heard when you twisted the cap? Odds are you know exactly what I’m talking about.

But have you ever wondered exactly what’s going on inside that bottle? If you’ve spent time around a protein processing plant or have worked at a wastewater treatment facility, you probably know the answer. Let’s take a closer look.

Why Is DAF, or Dissolved Air Flotation, Necessary?

The wastewater profession and its lingo are chock-full of acronyms. One of the best-known for a wastewater operator at a meat processing facility is “DAF,” pronounced “daf” or, sometimes, “D-A-F.” It stands for Dissolved Air Floatation, and it basically works like your soda bottle.

To understand this better, let me back up a little. Inside a poultry processing facility, meat is tossed, turned, tumbled, sliced, diced, washed and cut up. Throughout this process, very small bits of meat, fat and other proteins and fibrous particles are detached. This is the beginning of a long journey for these small particles.

The particles flow to a drain and mingle with other discarded parts of the chicken. Along with these larger chicken parts, like feet, heads, entrails and feathers, the small particles work their way to a screening room. Here, we often find large, rotating screens tasked with recovering valuable proteins, attached fats and feathers. These recovered materials are sent to rendering facilities and typically converted into different kinds of meals to be used as animal feed ingredients. The screens capture particles in the range of two hundredths (0.02) to four hundredths (0.04) of an inch and larger. The particles that pass through the screens then flow to wastewater for further treatment.

While it may sound like this water is a typical wastewater stream at this point, in fact, most conventional aerobic wastewater treatment plants cannot treat this water directly due to its high concentration of solids and nutrients. In most cases, to meet all state and federal discharge limits, additional reductions in loading must be achieved before reaching the wastewater plant’s biological treatment system.

How the DAF Does Its Job

Let’s come back around to the bottle of soda and the DAF. A DAF and its bubbles, like the ones you see rising to the top of your spda, will be just the ticket for cutting the loading to wastewater by 70-90%!

What you are observing when you open that bottle of carbonated drink is a result of a release of pressure built up inside the bottle. At the factory, the liquid was carbonated, meaning that CO2 was dissolved into your drink under pressure. Once you release that pressure, the CO2 starts to form gas bubbles, or, to be more technical, comes out of solution. This is exactly how a DAF works, only it uses ambient air injected directly into a waste stream under pressure to create the dissolved air, which will later be depressurized to reform gas bubbles.

But what is this accomplishing? Good question.

Remember the small bits of proteins and fats that made it through the screens? When pressure is released inside the DAF unit, the dissolved air starts to reform into very small air bubbles. As these bubbles rise to the surface, they attach to the small particles of solids suspended in the water, bringing them together and carrying them to the top. By doing this, the DAF system has removed the small particles that a screen could not.

Cool! What Now?

Now that that we have formed a semi-solid slurry (usually referred to as DAF Sludge or just Sludge), the DAF system scrapes the sludge into a collection hopper or tank, where it is ready for Denali to take over and turn this waste into gold. Not literal gold, of course, but something of value, for sure.

Now you understand that DAF Sludge is simply small bits of proteins, fats and fibrous materials that could not be removed by simple mechanical means. In the next blog, we will continue looking at the journey of these small particles and explain that, while small, they can still achieve greatness!

Until then, the next time you pop the top on your soda, remember there is more to the fizz than just a tingle to the taste buds.

To learn more about Denali’s beneficial use program, visit https://www.denaliwater.com/services/beneficial-use/.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512